
PhaseBio Pharmaceuticals, Inc. – NASDAQ:PHAS
PhaseBio Pharmaceuticals stock price today
PhaseBio Pharmaceuticals stock price monthly change
PhaseBio Pharmaceuticals stock price quarterly change
PhaseBio Pharmaceuticals stock price yearly change
PhaseBio Pharmaceuticals key metrics
Market Cap | N/A |
Enterprise value | 1.01M |
P/E | -0.02 |
EV/Sales | -0.10 |
EV/EBITDA | 0.03 |
Price/Sales | -0.34 |
Price/Book | -0.02 |
PEG ratio | N/A |
EPS | 0.59 |
Revenue | 818K |
EBITDA | 28.16M |
Income | 27.83M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -280.94% |
Oper. margin | 1041.79% |
Gross margin | -2.08% |
EBIT margin | 1041.79% |
EBITDA margin | 3443.23% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePhaseBio Pharmaceuticals stock price history
PhaseBio Pharmaceuticals stock forecast
PhaseBio Pharmaceuticals financial statements
Sep 2021 | 335K | -31.92M | -9529.55% |
---|---|---|---|
Dec 2021 | 158K | 87.82M | 55588.56% |
Mar 2022 | 117K | -11.28M | -9648.72% |
Jun 2022 | 208K | -16.78M | -8067.79% |
2022-05-16 | -0.66 | -0.23 |
---|---|---|
2022-08-12 | -0.31 | -0.34 |
Sep 2021 | 77725000 | 128.05M | 164.75% |
---|---|---|---|
Dec 2021 | 60540000 | 153.57M | 253.67% |
Mar 2022 | 38664000 | 141.05M | 364.83% |
Jun 2022 | 22166000 | 139.56M | 629.63% |
Sep 2021 | -6.13M | -638K | -1.32M |
---|---|---|---|
Dec 2021 | -19.99M | -1.65M | 7.09M |
Mar 2022 | -22.88M | -49K | -179K |
Jun 2022 | -10.41M | -58K | -415K |
PhaseBio Pharmaceuticals alternative data
Aug 2023 | 60 |
---|---|
Sep 2023 | 60 |
Oct 2023 | 60 |
Nov 2023 | 60 |
Dec 2023 | 60 |
Jan 2024 | 60 |
Feb 2024 | 60 |
Mar 2024 | 60 |
Apr 2024 | 60 |
May 2024 | 60 |
Jun 2024 | 60 |
Jul 2024 | 60 |
PhaseBio Pharmaceuticals other data
Period | Buy | Sel |
---|---|---|
Nov 2021 | 0 | 5766 |
May 2022 | 0 | 11248 |
Oct 2022 | 0 | 1784109 |
Patent |
---|
Grant Filling date: 22 Jun 2020 Issue date: 8 Mar 2022 |
Application Filling date: 1 Jul 2021 Issue date: 27 Jan 2022 |
Application Filling date: 31 Aug 2021 Issue date: 13 Jan 2022 |
Application Filling date: 20 Sep 2019 Issue date: 11 Nov 2021 |
Application Filling date: 17 Jun 2021 Issue date: 21 Oct 2021 |
Grant Utility: Metalloenzyme inhibitor compounds Filling date: 17 Jan 2020 Issue date: 5 Oct 2021 |
Grant Filling date: 8 May 2015 Issue date: 6 Jul 2021 |
Grant Utility: Metalloenzyme inhibitor compounds Filling date: 7 Sep 2018 Issue date: 22 Jun 2021 |
Application Filling date: 22 Jun 2020 Issue date: 11 Mar 2021 |
Grant Filling date: 26 Sep 2016 Issue date: 9 Mar 2021 |
Insider | Compensation |
---|---|
Mr. Jonathan P. Mow (1965) Pres, Chief Executive Officer & Director | $812,440 |
Dr. John S. Lee (1968) Chief Medical Officer | $582,230 |
Mr. John P. Sharp (1965) Chief Financial Officer | $516,420 |
-
What's the price of PhaseBio Pharmaceuticals stock today?
One share of PhaseBio Pharmaceuticals stock can currently be purchased for approximately $0.07.
-
When is PhaseBio Pharmaceuticals's next earnings date?
Unfortunately, PhaseBio Pharmaceuticals's (PHAS) next earnings date is currently unknown.
-
Does PhaseBio Pharmaceuticals pay dividends?
No, PhaseBio Pharmaceuticals does not pay dividends.
-
What is PhaseBio Pharmaceuticals's stock symbol?
PhaseBio Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "PHAS".
-
What is PhaseBio Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of PhaseBio Pharmaceuticals?
Shares of PhaseBio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are PhaseBio Pharmaceuticals's key executives?
PhaseBio Pharmaceuticals's management team includes the following people:
- Mr. Jonathan P. Mow Pres, Chief Executive Officer & Director(age: 60, pay: $812,440)
- Dr. John S. Lee Chief Medical Officer(age: 57, pay: $582,230)
- Mr. John P. Sharp Chief Financial Officer(age: 60, pay: $516,420)
-
How many employees does PhaseBio Pharmaceuticals have?
As Jul 2024, PhaseBio Pharmaceuticals employs 60 workers.
-
When PhaseBio Pharmaceuticals went public?
PhaseBio Pharmaceuticals, Inc. is publicly traded company for more then 6 years since IPO on 18 Oct 2018.
-
What is PhaseBio Pharmaceuticals's official website?
The official website for PhaseBio Pharmaceuticals is phasebio.com.
-
Where are PhaseBio Pharmaceuticals's headquarters?
PhaseBio Pharmaceuticals is headquartered at 1 Great Valley Pkwy Ste 30, Malvern, PENNSYLVANIA.
-
How can i contact PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals's mailing address is 1 Great Valley Pkwy Ste 30, Malvern, PENNSYLVANIA and company can be reached via phone at +1 610 981 6500.
PhaseBio Pharmaceuticals company profile:

PhaseBio Pharmaceuticals, Inc.
phasebio.comNASDAQ
60
Biotechnology
Healthcare
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Malvern, PENNSYLVANIA 19355
CIK: 0001169245
ISIN: US7172241090
CUSIP: 717224109